DOD Duchenne Muscular Dystrophy, Idea Development Award
ID: 354067Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/354067
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Duchenne Muscular Dystrophy (DMD) Idea Development Award for fiscal year 2024, aimed at promoting innovative research that could significantly advance treatment options for individuals affected by DMD. This grant supports high-risk, high-reward research projects that are in the early stages of development, with a focus on generating impactful data and new avenues of investigation, particularly for new investigators transitioning into DMD research. The total estimated funding for this program is $4.48 million, with a maximum award amount of $350,000 over a two-year period, and applications must be submitted by August 22, 2024, following a pre-application deadline of August 1, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524DMDRPIDA_GG.pdf
    The DOD FY24 Duchenne Muscular Dystrophy (DMD) Idea Development Award aims to promote innovative research in the treatment of DMD, enhancing the quality of life for individuals affected by this condition, particularly within military families. The program, part of the Defense Health Program, has allocated $10 million in funding for fiscal year 2024, encouraging applications that focus on the development of effective therapies across various life stages and conditions related to DMD. Key application deadlines include the Pre-Application Submission by August 1, 2024, and the Full Application Submission by August 22, 2024. Eligible applicants include both extramural and intramural organizations, with a focus on new investigators transitioning to DMD research. The award supports high-risk, high-reward research that has the potential to lead to significant advancements in DMD treatment. Applications must demonstrate innovation and feasibility based on strong scientific rationale, with funding limited to a maximum of $350,000 over a two-year period. Notably, clinical trials are not permitted. All submissions must follow specified guidelines to ensure clarity, coherence, and compliance with program objectives, reaffirming the program's commitment to impactful DMD research.
    Similar Opportunities
    DOD Duchenne Muscular Dystrophy, Clinical/Translational Research Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering a grant opportunity for the Duchenne Muscular Dystrophy Research Program's Clinical/Translational Research Award (CTRA) for fiscal year 2025. This funding initiative aims to support advanced translational research that accelerates promising ideas in Duchenne muscular dystrophy (DMD) into clinical applications, particularly focusing on therapies effective across all age groups, including infants and nonambulatory individuals. With an estimated total program funding of approximately $8.56 million, the program anticipates awarding around five grants, encouraging collaborations with early-career investigators and requiring applications to include preliminary data relevant to DMD. Interested applicants should note that a pre-application is due by July 25, 2025, with full applications due by August 8, 2025; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DOD Amyotrophic Lateral Sclerosis, Therapeutic Development Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) to support innovative research aimed at developing therapies for Amyotrophic Lateral Sclerosis (ALS). This grant program seeks applications that demonstrate proof-of-concept efficacy in preclinical models of ALS, with a focus on empirical therapeutic studies and the development of mechanism-specific biomarkers to enhance trial design and patient selection. With an estimated total funding of approximately $9.8 million, the program anticipates awarding about four grants, each capped at $1.5 million for a maximum duration of three years. Interested applicants must submit a pre-application by June 6, 2025, followed by a full application due by August 27, 2025. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Rare Cancers, Idea Development Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering a funding opportunity for the Rare Cancers Research Program (RCRP) Idea Development Award for fiscal year 2025. This grant aims to support innovative research that explores new ideas and develops impactful strategies in the area of rare cancers, which are defined as those affecting six or fewer individuals per 100,000 annually in the U.S. Eligible applicants include various organizations, and the program encourages interdisciplinary collaboration among military, academic, and industry sectors to enhance health outcomes for military Service Members, Veterans, and the broader public. The total estimated program funding is $6,860,000, with a funding limit of $490,000 per application. Key deadlines include a pre-application due by July 1, 2025, and a full application by October 6, 2025. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    DoD Peer Reviewed Medical Research Program, Clinical Trial Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering a grant opportunity under the Peer Reviewed Medical Research Program (PRMRP) for the fiscal year 2025, specifically for the Clinical Trial Award (CTA). This program aims to support the rapid implementation of clinical trials that can significantly impact the treatment or management of diseases relevant to military health, with a focus on areas such as autoimmune disorders, cardiovascular health, infectious diseases, and neuroscience. Approximately $32 million is available for this initiative, with an expected four awards, each capped at $8 million, and applications are due by July 21, 2025. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507 for further assistance.
    DoD Melanoma, Idea Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY25 Melanoma Research Program Idea Award to support innovative and exploratory research related to melanoma. This grant aims to fund high-risk, potentially high-reward projects that focus on areas such as melanoma prevention, rare melanoma research, or survivorship impacts, with a maximum direct cost of $400,000 available for each project over a two-year period. The program is particularly significant for advancing melanoma detection, treatment, and survivorship, especially in the context of military health concerns. Interested applicants must submit a pre-application by June 30, 2025, followed by a full application due by October 1, 2025, with a total funding pool of approximately $5.76 million available for about nine awards. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Peer Reviewed Medical Research Program, Technology/Therapeutic Development Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY25 Peer Reviewed Medical Research Program (PRMRP) Technology/Therapeutic Development Award (TTDA) to support the translation of promising preclinical findings into clinical applications for military personnel, veterans, and their families. This grant aims to facilitate the development of products that address military-related health challenges, including prevention, detection, diagnosis, treatment, or quality of life improvements, with a focus on innovative approaches in areas such as autoimmune disorders and infectious diseases. With an estimated total program funding of approximately $41.25 million available for up to 11 awards, applicants must submit a two-step application process, including a pre-application and a full application, by the closing date of July 21, 2025. For further inquiries, interested parties can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    DOD Amyotrophic Lateral Sclerosis, Therapeutic Idea Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Therapeutic Idea Award (TIA) under the fiscal year 2025 Amyotrophic Lateral Sclerosis Research Program (ALSRP). This grant aims to support innovative, high-risk research proposals focused on drug or therapy development for Amyotrophic Lateral Sclerosis (ALS), with an emphasis on generating preliminary data for future therapeutic investigations. The program has a total funding amount of approximately $10.8 million, with individual awards capped at $600,000 and a performance period not exceeding two years. Interested applicants must submit pre-applications by June 6, 2025, and full applications by August 27, 2025; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DOD Amyotrophic Lateral Sclerosis, Clinical Outcomes and Biomarkers Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is inviting applications for the Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) for fiscal year 2025. This grant aims to support the development and validation of clinical outcomes and biomarkers specifically for enhancing clinical trials in Amyotrophic Lateral Sclerosis (ALS), focusing on targeted therapies or genetic mutations rather than broad applicability to all patients. With an estimated total program funding of $6.2 million, the program anticipates awarding approximately five grants, each with a maximum budget of $750,000 for a duration of up to three years. Interested applicants must submit a pre-application by June 6, 2025, followed by a full application due by August 27, 2025. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Military Burn, Discovery Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY25 Military Burn Research Program (MBRP) Discovery Award to support innovative research aimed at improving combat-relevant burn care for military personnel. This grant encourages exploratory, hypothesis-driven, or hypothesis-generating research that is novel and based on a strong scientific rationale, with the goal of generating preliminary data for future translational and clinical research. The program has an estimated total funding of $800,000, with up to four awards available, each capped at $200,000 over a maximum of two years. Interested applicants, including both domestic and foreign organizations, must submit pre-applications and full applications via eBRAP or Grants.gov by the closing date of September 8, 2025, and can contact the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Melanoma, Survivorship Research Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY25 Melanoma Survivorship Research Award to support innovative research aimed at enhancing the health and well-being of melanoma survivors and their caregivers. This grant encourages collaborative research that integrates insights from melanoma consumers, with a focus on various aspects of survivorship, including psychological impacts, symptom management, and healthcare delivery challenges, while explicitly excluding studies limited to animal models or survival rates without quality of life considerations. The total estimated program funding is $2,320,000, with a maximum award amount of $725,000 per project over a three-year performance period. Interested applicants must submit a pre-application by September 10, 2025, followed by a full application due by October 1, 2025, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.